In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/15/13 | UPLOAD | SEC-generated letter |
|
2 | |
| 09/30/13 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
43 | |
| 09/17/13 | UPLOAD | SEC-generated letter |
|
5 | |
| 08/20/13 | S-1 | General form of registration statement for all companies including face-amount certificate companies |
|
44 |
